Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Weineng Feng's publication output changed over time?
ScholarIQpublication output · 2013–2025
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2025.
1
1
2
2
1
2
1
1
20132014201920212022202320242025
What are the most-cited papers on Weineng Feng?
ScholarIQmost cited works
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, G. Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Lei Feng, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiao‐Jing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang
The Lancet Oncology. 2021461 Citations
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant
HARMONi-A Study Investigators, Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Fei Xu, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Lee Jia, Xu Shen, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Jun‐Guo Lu, Jifeng Feng, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, Weineng Feng, Wen Li, Jian‐An Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Zhang
JAMA. 2024185 CitationsOPEN ACCESS
Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network
Chao Zhang, Xing Sun, Kang Dang, Ke Li, Xiaowei Guo, Chang Jia, Zongqiao Yu, Feiyue Huang, Yunsheng Wu, Yunsheng Wu, Zhu Liang, Zaiyi Liu, Xue-gong Zhang, Xinglin Gao, Shaohong Huang, Jie Qin, Weineng Feng, Tao Zhou, Yanbin Zhang, Wei-jun Fang, Mingfang Zhao, Xue‐Ning Yang, Qing Zhou, Yi‐Long Wu, Yi‐Long Wu, Wen‐Zhao Zhong
The Oncologist. 2019168 CitationsOPEN ACCESS
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang
The Lancet Respiratory Medicine. 2019139 Citations
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
Ziyou Lin, Jingwei Li, Jian Zhang, Weineng Feng, Jiaye Lu, Xiaofan Ma, Wen Ding, Shumin Ouyang, Jin‐Jian Lu, Peibin Yue, Guohui Wan, Peiqing Liu, Xiaolei Zhang
Cancer Research. 2023138 Citations
Related on ScholarIQ
First People's Hospital of Foshan
Institution
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Paper
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant
Paper
Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network
Paper
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Paper
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
Paper